Zimmer Biomet Holdings, Inc. $ZBH Stake Cut by Kingswood Wealth Advisors LLC

Kingswood Wealth Advisors LLC reduced its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 6.9% in the 2nd quarter, Holdings Channel reports. The fund owned 2,426 shares of the medical equipment provider’s stock after selling 179 shares during the period. Kingswood Wealth Advisors LLC’s holdings in Zimmer Biomet were worth $221,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the business. Vanguard Group Inc. lifted its stake in Zimmer Biomet by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 23,052,925 shares of the medical equipment provider’s stock worth $2,609,130,000 after acquiring an additional 166,763 shares in the last quarter. Dodge & Cox increased its position in Zimmer Biomet by 2.3% in the 1st quarter. Dodge & Cox now owns 19,564,454 shares of the medical equipment provider’s stock worth $2,214,305,000 after purchasing an additional 446,018 shares during the last quarter. Ameriprise Financial Inc. increased its position in Zimmer Biomet by 236.0% in the 1st quarter. Ameriprise Financial Inc. now owns 4,568,287 shares of the medical equipment provider’s stock worth $517,039,000 after purchasing an additional 3,208,596 shares during the last quarter. JPMorgan Chase & Co. increased its position in Zimmer Biomet by 251.3% in the 1st quarter. JPMorgan Chase & Co. now owns 2,081,381 shares of the medical equipment provider’s stock worth $235,571,000 after purchasing an additional 1,488,918 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its position in Zimmer Biomet by 2.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,058,898 shares of the medical equipment provider’s stock worth $233,009,000 after purchasing an additional 58,060 shares during the last quarter. 88.89% of the stock is owned by hedge funds and other institutional investors.

Zimmer Biomet Stock Performance

Shares of NYSE ZBH opened at $94.79 on Friday. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.96 and a current ratio of 1.87. The firm has a market cap of $18.78 billion, a price-to-earnings ratio of 23.06, a P/E/G ratio of 2.18 and a beta of 0.67. The business’s 50-day simple moving average is $101.31 and its 200-day simple moving average is $98.25. Zimmer Biomet Holdings, Inc. has a 52 week low of $89.22 and a 52 week high of $114.72.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.98 by $0.09. The firm had revenue of $2.08 billion for the quarter, compared to analyst estimates of $2.06 billion. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The company’s revenue was up 7.0% on a year-over-year basis. During the same quarter last year, the firm posted $2.01 EPS. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, equities research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be issued a $0.24 dividend. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $0.96 dividend on an annualized basis and a yield of 1.0%. Zimmer Biomet’s dividend payout ratio (DPR) is 23.36%.

Insider Transactions at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 1,500 shares of the firm’s stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $104.15, for a total value of $156,225.00. Following the sale, the senior vice president owned 6,833 shares of the company’s stock, valued at $711,656.95. This trade represents a 18.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 1.39% of the stock is owned by company insiders.

Analysts Set New Price Targets

ZBH has been the topic of several research reports. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Zimmer Biomet in a research report on Wednesday. UBS Group upped their target price on Zimmer Biomet from $91.00 to $96.00 and gave the stock a “sell” rating in a research report on Friday, August 8th. Evercore ISI dropped their target price on Zimmer Biomet from $106.00 to $104.00 and set an “in-line” rating on the stock in a research report on Tuesday, October 7th. Royal Bank Of Canada set a $111.00 price objective on Zimmer Biomet in a report on Friday. Finally, Redburn Partners set a $130.00 price objective on Zimmer Biomet in a report on Thursday, September 18th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, eight have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, Zimmer Biomet currently has an average rating of “Hold” and an average target price of $112.67.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.